Design Therapeutics DSGN Cash Flow Statement (2020-2026)

NASDAQ DSGN
$10.56 -0.24 (-2.22%)
As of: Nov 10, 2026 · 12:13 PM EST
Reported Financials

Design Therapeutics Quarterly Cash Flow Statement

Periods 27 quarters
Latest Sep 2026

Design Therapeutics reported cash from operations of -$15.38M and free cash flow of -$15.39M for the quarter ended Sep 2026, down 37.8% year over year. This cash flow statement covers 27 quarters of results from Mar 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-11.07M-13.27M-15.00M-17.70M-17.34M-19.29M-19.94M-15.79M-11.84M-11.11M-11.79M-13.04M-13.65M-17.72M-19.08M-17.00M-16.00M-17.64M-20.17M-20.29M
Depreciation and DepletionDep. & Depletion
0.08M0.08M0.09M0.11M0.12M0.13M0.13M0.14M0.14M0.14M0.15M0.15M0.15M0.16M0.15M0.16M0.16M0.16M0.15M0.14M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.08M0.08M0.09M0.11M0.12M0.13M0.13M0.14M0.14M0.14M0.15M0.15M0.15M0.16M0.15M0.16M0.16M0.16M0.15M0.14M
Share-based CompensationStock Comp.
1.56M2.36M2.62M2.87M3.08M3.43M3.72M3.22M2.72M3.18M3.30M3.12M3.47M3.54M3.99M3.59M3.44M3.92M3.87M4.05M
Other non-cash itemsOther Non-Cash
0.01M0.01M0.02M0.01M0.01M0.01M0.01M0.01M0.01M0.00M0.00M0.00M0.00M0.00M0.00M-0.01M-0.01M0.07M0.07M0.00M
Change in Working Capital
Change in Accrued ExpensesChange Accrued Exp.
-0.03M0.22M1.60M3.16M0.42M-1.75M3.07M0.24M-2.81M-2.52M-0.72M1.02M1.01M-0.30M0.54M2.41M1.84M-2.51M0.96M1.44M
Change in Other Operating AssetsOther Assets Change
-0.20M1.24M-0.22M1.90M0.47M-1.19M-0.60M0.64M-0.82M0.41M0.63M-0.66M-0.61M1.41M-0.45M-0.46M0.88M0.29M0.39M0.74M
Change in Other Operating LiabilitiesOther Liabilities Change
Other Working Capital ChangesOther WC Changes
0.20M-1.24M0.22M-1.90M-0.47M1.19M0.60M-0.64M0.82M-0.41M-0.63M0.66M0.61M-1.41M0.45M0.46M-0.88M-0.29M-0.39M-0.74M
Cash from OperationsCash from Ops.
-9.23M-11.83M-10.50M-13.90M-15.09M-17.42M-13.80M-14.53M-12.80M-12.44M-11.26M-9.55M-9.86M-16.79M-14.44M-11.16M-11.97M-16.43M-15.52M-15.38M
Investing Activities
Capital ExpendituresCapex
0.35M0.08M0.24M0.31M0.29M0.09M0.09M0.05M0.03M0.20M0.16M-0.02M0.07M0.09M0.03M0.02M0.02M
Change in Property, Plant and EquipmentChange in PP&E
-0.35M-0.08M-0.24M-0.31M-0.29M-0.09M-0.09M-0.05M-0.03M-0.20M-0.16M0.02M-0.07M-0.09M-0.03M-0.02M-0.02M
Purchase of InvestmentsInvestments Purchased
49.91M94.01M61.01M33.62M62.37M54.57M74.15M45.66M53.63M66.51M64.37M86.55M39.53M78.08M87.62M52.59M12.42M29.80M
Sale and Maturity of InvestmentsInvestments Sold
0.20M0.49M1.23M30.94M60.24M53.44M74.44M69.89M79.74M66.47M81.13M60.67M66.21M94.49M59.74M84.59M76.08M45.00M27.50M30.00M
Cash from Investing ActivitiesCash from Investing
-50.06M0.41M-156.96M-63.39M-1.06M19.73M11.98M15.27M5.56M20.62M27.33M-5.83M1.83M7.87M20.12M6.51M-11.58M-7.59M15.06M0.19M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Net Long-Term Debt Issued (Repaid)Net LT Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
0.00M0.16M0.15M0.02M0.01M0.40M0.02M0.01M0.00M0.01M0.02M0.04M25.03M19.93M0.14M17.53M
Net Shares Issued and RepurchasedNet Shares Issued
0.00M0.16M0.15M0.02M0.01M0.40M0.02M0.01M0.00M0.01M0.02M0.04M25.03M19.93M0.14M17.53M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.00M0.16M0.15M0.02M0.01M0.40M0.02M0.01M0.00M0.01M0.02M0.04M25.03M19.93M0.14M17.53M
Cash from Financing ActivitiesCash from Financing
0.19M0.16M-0.20M0.15M0.13M0.01M0.50M0.02M0.23M0.00M0.26M0.02M0.36M0.04M25.32M19.93M0.61M17.53M
Additional items
Change in Cash
-59.09M-11.26M-167.66M-77.14M-16.02M2.31M-1.61M0.75M-6.74M8.20M16.30M-15.37M-7.77M-8.90M6.04M-4.62M1.77M-4.09M0.14M2.35M
Ending Cash Balance
298.57M287.31M119.65M42.52M26.50M28.81M27.20M27.94M21.20M29.40M45.70M30.33M22.56M13.67M19.70M15.09M16.86M12.77M12.91M15.25M
Free Cash FlowFCF
-9.58M-11.90M-10.74M-14.21M-15.38M-17.51M-13.89M-14.59M-12.83M-12.63M-11.42M-9.53M-9.86M-16.86M-14.53M-11.16M-12.00M-16.43M-15.55M-15.39M
Net Cash FlowNCF
-59.09M-11.26M-167.66M-77.14M-16.02M2.31M-1.82M0.75M-6.74M8.20M16.30M-15.37M-7.77M-8.90M6.04M-4.62M1.77M-4.09M0.14M2.35M
Interest Paid

Design Therapeutics Cash Flow Statement API

Pull Design Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=DSGN&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY